PharmaEngine Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Hong-Ren Wang
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 5yrs |
| CEO ownership | 0.02% |
| Management average tenure | no data |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Would PharmaEngine, Inc. (GTSM:4162) Be Valuable To Income Investors?
Mar 30
How Much Did PharmaEngine's(GTSM:4162) Shareholders Earn From Share Price Movements Over The Last Five Years?
Feb 18Is PharmaEngine, Inc.'s (GTSM:4162) Stock On A Downtrend As A Result Of Its Poor Financials?
Jan 14
We're Not Counting On PharmaEngine (GTSM:4162) To Sustain Its Statutory Profitability
Dec 10CEO
Hong-Ren Wang
Mr. Hong-Ren Wang, Ph D., is President of PharmaEngine, Inc. since January 20, 2021 and serves as Chief Executive Officer. Mr. Wang holds Ph.D. degree in Materials Science and Engineering from Massachusett...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Representative Director | no data | NT$2.06m | no data | |
| Chairman | less than a year | NT$6.50m | no data | |
| Representative Director | 8yrs | NT$2.06m | no data | |
| Representative Director | 7.7yrs | NT$2.06m | no data | |
| Independent Director | 6.6yrs | NT$1.68m | 0.0021% NT$ 217.5k | |
| Director | 4.4yrs | NT$2.07m | no data | |
| Independent Director | 4.4yrs | NT$1.68m | no data | |
| Independent Director | no data | NT$1.68m | no data | |
| Representative Director | no data | NT$2.06m | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
Experienced Board: 4162's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/07 19:58 |
| End of Day Share Price | 2026/01/07 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PharmaEngine, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nam Park | HSBC |
| Hengyu Fu | Masterlink Securities Corp. |
| Toshinori Katsuki | Nomura Securities Co. Ltd. |